Looks like you’re on the UK site. Choose another location to see content specific to your location
Lilly reports positive clinical trial data for breast cancer drug
Lilly has announced data from a pre-planned interim analysis of the phase III trial MONARCH 3, demonstrating the benefits of its new breast cancer drug abemaciclib.
The CDK4 and CDK6 inhibitor was evaluated in combination with an aromatase inhibitor – letrozole or anastrozole – compared to treatment with an aromatase inhibitor alone in women with HR-positive, HER2-negative advanced breast cancer.
Abemaciclib met its primary endpoint by demonstrating a statistically significant improvement in progression-free survival, while improvement was shown in a key secondary endpoint of objective response rate.
Following this interim analysis, Lilly intends to begin global submissions of these results in the third quarter of 2017, following on from MONARCH 1 and MONARCH 2 submissions during the second quarter.
Dr Levi Garraway, senior vice-president for global development and medical affairs at Lilly Oncology, said: "Today marks another important milestone in our clinical development programme for abemaciclib, a drug we believe has the potential to be best in class."
This drug is also being evaluated as a treatment for lung cancer, brain metastases and pancreatic cancer.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard